(Q35917230)

11 August 2017

1 reference

title

Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'. (English)

1 reference

ORCID Public Data File 2021

11 August 2017

0 references

1 reference

1 reference

author name string

Douglas N Fish

series ordinal

1

1 reference

11 August 2017

1 October 2003

1 reference

Expert Review of Anti-infective Therapy

11 August 2017

1 reference

11 August 2017

1

1 reference

11 August 2017

371-387

1 reference

11 August 2017

3

1 reference

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

11 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Antimicrobial-Drug Prescription in Ambulatory Care Settings, United States, 1992–2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Nontyphoidal salmonellosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

The clinical pharmacokinetics of levofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Gatifloxacin, an advanced 8-methoxy fluoroquinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Widespread use of fluoroquinolones versus emerging resistance in pneumococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Maintaining fluoroquinolone class efficacy: review of influencing factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

A critical review of the fluoroquinolones: focus on respiratory infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Fluoroquinolone toxicity profiles: a review focusing on newer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

The safety profile of the fluoroquinolones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with beta-lactam-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Effects of three fluoroquinolones on QT interval in healthy adults after single doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Fluoroquinolone-associated tendinopathy: a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Quinolone arthropathy in animals versus children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.371

21 January 2018

Identifiers

DOI

10.1586/14787210.1.3.371

1 reference

11 August 2017

1 reference

PubMed ID

15482135